Yanmei Xu

1.3k total citations · 1 hit paper
21 papers, 1.0k citations indexed

About

Yanmei Xu is a scholar working on Molecular Biology, Oncology and Computational Theory and Mathematics. According to data from OpenAlex, Yanmei Xu has authored 21 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Computational Theory and Mathematics. Recurrent topics in Yanmei Xu's work include Computational Drug Discovery Methods (4 papers), MicroRNA in disease regulation (4 papers) and Melanoma and MAPK Pathways (3 papers). Yanmei Xu is often cited by papers focused on Computational Drug Discovery Methods (4 papers), MicroRNA in disease regulation (4 papers) and Melanoma and MAPK Pathways (3 papers). Yanmei Xu collaborates with scholars based in China, United States and United Kingdom. Yanmei Xu's co-authors include Douglas J. DeMarini, Jeffrey R. Infante, Leslie A. Fecher, Ngocdiep T. Le, Razelle Kurzrock, Wells A. Messersmith, Carlos Becerra, Keith T. Flaherty, Vijay Peddareddigari and Donna S. Cox and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Yanmei Xu

19 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

2012 424 citations Jeffrey R. Infante, Leslie A. Fecher et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yanmei Xu China	9	736	528	194	143	121	21	1.0k
Sujatha Nallapareddy United States	10	509 0.7×	440 0.8×	122 0.6×	141 1.0×	103 0.9×	16	790
Wanleng Deng United States	14	907 1.2×	659 1.2×	236 1.2×	272 1.9×	93 0.8×	20	1.4k
Yogindra Persaud United States	6	619 0.8×	368 0.7×	99 0.5×	151 1.1×	136 1.1×	12	818
Allison Marlow United States	3	724 1.0×	447 0.8×	80 0.4×	137 1.0×	166 1.4×	3	946
Nyam Kamsu-Kom France	10	662 0.9×	615 1.2×	80 0.4×	117 0.8×	84 0.7×	12	1.0k
Alexa B. Turke United States	6	772 1.0×	682 1.3×	201 1.0×	214 1.5×	304 2.5×	6	1.1k
Eric W. Joseph United States	7	964 1.3×	516 1.0×	97 0.5×	113 0.8×	260 2.1×	9	1.2k
Aphrothiti J. Hanrahan United States	7	699 0.9×	423 0.8×	317 1.6×	334 2.3×	162 1.3×	9	1.1k
Laura M. Bruzek United States	11	827 1.1×	530 1.0×	134 0.7×	172 1.2×	163 1.3×	15	1.2k
Clive Morris United Kingdom	14	735 1.0×	629 1.2×	249 1.3×	468 3.3×	208 1.7×	38	1.4k

Countries citing papers authored by Yanmei Xu

Since Specialization

Citations

This map shows the geographic impact of Yanmei Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanmei Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanmei Xu more than expected).

Fields of papers citing papers by Yanmei Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanmei Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanmei Xu. The network helps show where Yanmei Xu may publish in the future.

Co-authorship network of co-authors of Yanmei Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Yanmei Xu. A scholar is included among the top collaborators of Yanmei Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yanmei Xu. Yanmei Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Qiu, Yi, Huan Zeng, Lihua Yao, et al.. (2025). Hexokinase 2-mediated histone H3K18la promotes PAI-1-dependent thrombosis in acute myeloid leukemia via tumor-endothelial crosstalk. Nature Communications. 16(1). 10168–10168.

Liao, Kaili, Beining Zhang, Xue Zhang, et al.. (2025). The role of intratumoral microbiome in the occurrence, proliferation, metastasis of colorectal cancer and its underlying therapeutic strategies. Ageing Research Reviews. 111. 102820–102820. 2 indexed citations

Zhang, Jing, Yanmei Xu, Shuqi Li, et al.. (2025). The role of METTL14 in the progression of chronic myeloid leukemia. Hematology. 30(1). 2535819–2535819.

Xu, Yanmei, et al.. (2024). Exploring the molecular mechanism of action of curcumin for the treatment of diabetic retinopathy, using network pharmacology, molecular docking, and molecular dynamics simulation. 8(0). e24008–e24008. 2 indexed citations

Wu, Lei, Dezhi Li, Yanmei Xu, et al.. (2018). Radiosensitizing effects of miR‐18a‐5p on lung cancer stem‐like cells via downregulating both ATM and HIF‐1α. Cancer Medicine. 7(8). 3834–3847. 55 indexed citations

Li, Yan, et al.. (2018). Pharmacokinetics, Safety, and Tolerability of Lamotrigine Chewable/Dispersible Tablet Following Repeat‐Dose Administration in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development. 7(6). 627–633. 6 indexed citations

Chen, Xu, Yanmei Xu, Xingyun Liao, et al.. (2016). Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer. Tumor Biology. 37(9). 11927–11936. 67 indexed citations

Huiban, Mickaël, Christopher Coello, Yanmei Xu, et al.. (2016). Investigation of the Brain Biodistribution of the Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitor [18F]GSK2647544 in Healthy Male Subjects. Molecular Imaging and Biology. 19(1). 153–161. 14 indexed citations

Fong, Regan, et al.. (2016). Evaluation of the safety, pharmacokinetics, pharmacodynamics, and drug-drug interaction potential of GSK2647544 in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics. 54(12). 935–949. 6 indexed citations

10.

Jiang, Zefei, Zhimin Shao, Qingyuan Zhang, et al.. (2016). Efficacy and safety of denosumab from a phase III, randomized, active-controlled study compared with zoledronic acid in patients of Asian ancestry with bone metastases from solid tumors.. Journal of Clinical Oncology. 34(15_suppl). 10116–10116. 4 indexed citations

11.

Zhang, Luping, Yanmei Xu, Dan Zhang, et al.. (2016). Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. Radiation Oncology. 11(1). 60–60. 23 indexed citations

12.

Xu, Yanmei, Xingyun Liao, Xiewan Chen, et al.. (2015). Regulation of miRNAs Affects Radiobiological Response of Lung Cancer Stem Cells. BioMed Research International. 2015. 1–7. 8 indexed citations

13.

Xu, Yanmei, James Roger, Colin H. Macphee, et al.. (2014). Platelet Aggregation Unchanged by Lipoprotein-Associated Phospholipase A2 Inhibition: Results from an In Vitro Study and Two Randomized Phase I Trials. PLoS ONE. 9(1). e83094–e83094. 17 indexed citations

14.

Hilpert, Jan, Kai Wu, Gary S. Collins, et al.. (2014). An adaptive design to investigate the effect of ketoconazole on pharmacokinetics of GSK239512 in healthy male volunteers. The Journal of Clinical Pharmacology. 55(5). 505–511. 5 indexed citations

15.

Zhang, Luping, Xingyun Liao, Yanmei Xu, et al.. (2013). Efficacy and Safety of Endostar^®Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas. Asian Pacific Journal of Cancer Prevention. 14(7). 4255–4259. 12 indexed citations

16.

Liao, Rongxia, et al.. (2013). Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia. Hematology. 18(4). 191–197. 6 indexed citations

17.

Kim, Kevin B., Richard Kefford, Anna C. Pavlick, et al.. (2012). Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. Journal of Clinical Oncology. 31(4). 482–489. 356 indexed citations

18.

Infante, Jeffrey R., Leslie A. Fecher, Gerald S. Falchook, et al.. (2012). Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. The Lancet Oncology. 13(8). 773–781. 424 indexed citations breakdown →

19.

Naing, Aung, Razelle Kurzrock, Laurel M. Adams, et al.. (2010). A Comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors. Investigational New Drugs. 30(1). 327–334. 16 indexed citations

20.

Borthakur, Gautam, James M. Foran, Tapan M. Kadia, et al.. (2010). GSK1120212, a MEK1/MEK2 Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity In a Dose Rising Trial In Subjects with AML and Other Hematologic Malignancies. Blood. 116(21). 3281–3281. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact